Whilst in contrast, post hoc analyses of clinical trials have found type 2 diabetes duration and beta cell function do not modify glycaemic outcomes with GLP1-RA [19, 32, 33], this may reflect trial inclusion criteria as participants had relatively higher beta cell function compared with population-based cohorts [34]. Here, GCG is linked to type 2 diabetes mellitus.